Table 1.
Patients’ clinical features at baseline.
| Sham | RIPC | p Value | ||
|---|---|---|---|---|
| GENDER | Male | 12 (80%) | 10 (67%) | 0.68 |
| Female | 3 (20%) | 5 (33%) | ||
| Age | 64 | 68 | 0.56 | |
| BMI | 26.6 | 25.4 | 0.23 | |
| COMORBIDITIES | Hypertension | 11 (73%) | 11 (73%) | 1.00 |
| Smoking habit | 10 (67%) | 8 (53%) | 0.74 | |
| Dyslipidemia | 10 (67%) | 7 (47%) | 0.46 | |
| Previous AMI | 7 (47%) | 5 (33%) | 0.71 | |
| CKD (eGFR < 30 mL/min/m2) | 4 (27%) | 1 (7%) | 0.33 | |
| Chronic heart failure | 3 (20%) | 1 (7%) | 0.30 | |
| Cerebral vascular disease |
2 (13%) | 1 (7%) | 0.50 | |
| Previous cancer | 0 | 3 (20%) | 0.11 | |
| COPD | 0 | 1 (7%) | 0.50 | |
| ACS CLASSIFICATION | NSTEMI | 9 (60%) | 9 (60%) | 1.00 |
| UA | 6 (40%) | 6 (40%) | ||
| MEDICATION BEFORE | ASA | 8 (53%) | 5 (33%) | 0.52 |
| ADMISSION | ACE-I/ARBs | 7 (47%) | 9 (60%) | 0.69 |
| Beta blockers | 6 (40%) | 6 (40%) | 1.00 | |
| Statins | 5 (33%) | 4 (27%) | 0.56 | |
| Ca2+ channel blockers | 5 (33%) | 1 (7%) | 0.09 | |
| Nitrates | 2 (13%) | 3 (20%) | 0.55 | |
| Clopidogrel | 0 | 2 (13%) | 0.26 | |
| CLINICAL FEATURES AT ADMISSION | Mean eGFR (mL/min/m2) | 75.9 | 80.7 | 0.58 |
| Left ventricular ejection fraction |
57% | 54% | 0.45 | |
| Time from onset to admission (h) |
42 | 44 | 0.78 | |
| Hemoglobin (g/dL) | 14.1 | 13.6 | 0.36 | |
| CLINICAL FEATURES DURING | Mean number of implanted stents | 2 | 2 | 1 |
| HOSPITALIZATION | Mean contrast agent volume (mL) | 237 | 228 | 0.77 |
| NUMBER OF VESSELS | 1 | 2 (13%) | 5 (33%) | 0.36 |
| AFFECTED BY | 2 | 7 (47%) | 5 (33%) | |
| SIGNIFICANT DISEASE | 3 | 6 (40%) | 5 (33%) | |
|
COMPLICATIONS
DURING |
New AMI during hospitalization | 0 | 1 (7%) | 0.5 |
| HOSPITALIZATION | Intra stent thrombosis |
0 | 0 | |
| Additional PCI | 3 (20%) | 2 (13%) | 0.5 | |
| Mortality during hospitalization |
0 | 0 | ||
| BARC bleeding | 0 | 15 (100%) | 12 (80%) | 0.09 |
| 1 | 0 | 1 (7%) | ||
| 2 | 0 | 2 (13%) |